The US push to cut drug prices via a 'Most-Favoured Nation' policy may shift financial burdens to emerging markets like India, warns GTRI. Pharmaceutical giants could seek higher prices and stricter IP protections in India to offset losses. Experts urge India to resist TRIPS-plus trade demands and protect its low-cost generics model vital to global health access.